广东精诚粤衡律师事务所 股东大会法律意见书 广东精诚粤衡律师事务所 关于广东宝莱特医用科技股份有限公司 2024 年年度股东大会的 法律意见书 致：广东宝莱特医用科技股份有限公司（下称"贵公司"） 广东精诚粤衡律师事务所（以下简称"本所"）接受贵公司的委托，就贵 公司 2024 年年度股东大会（以下简称"本次股东大会"）出具法律意见。为此， 本所律师查阅了有关贵公司本次股东大会的资料，并指派律师出席了贵公司于 2025 年 6 月 6 日召开的本次股东大会。 本所律师根据《中华人民共和国公司法》、《中华人民共和国证券法》、 《广东宝莱特医用科技股份有限公司章程》等法律法规的规定，就贵公司本次 股东大会的召集、召开程序、出席会议的人员资格、股东大会议案和股东大会 的表决程序和表决结果等事项发表法律意见，不对本次股东大会所审议议案的 内容以及在议案中所涉及的事实和数据的真实性和准确性等问题发表意见。 本所律师是依据本法律意见书出具日以前已经发生的事实的了解和对法律 的理解发表法律意见。 贵公司本次股东大会由董事会召集。 贵公司董事会于 2025年 4月 24日召开了第八届董事会第二十二次会议，并 于 2025年 ...

Group 1 - The core business of Baolait Medical Technology Co., Ltd. includes research, production, sales, and service of medical device products, with key products such as monitoring devices, ECG machines, infusion pumps, pulse oximeters, central monitoring systems, and wearable medical products [1] - As of the first quarter of 2025, Baolait reported a revenue of 248 million yuan, a year-on-year decrease of 7.17%, and a net profit of 14.45 million yuan, a year-on-year increase of 298.35%, with a gross profit margin of 27.39% [1] - The company holds a total of 70 authorized invention patents, 278 utility model patents, 49 design patents, 3 international patents, 115 software copyrights, and 122 trademarks, along with 87 medical device registration certificates [1] Group 2 - Baolait's current price-to-earnings (P/E) ratio (TTM) is -31.90, with a price-to-book (P/B) ratio of 1.64 and a total market capitalization of 1.934 billion yuan [2] - The industry average P/E ratio is 48.81, while the industry median P/E ratio is 35.46, indicating that Baolait's valuation metrics are significantly lower than the industry averages [2]

Group 1 - The company reported a net profit attributable to shareholders of approximately -71 million yuan for 2024, primarily due to external environment factors, adjustments in business model, and a decrease in orders, leading to reduced operating income and increased management and financial expenses [4] - In October 2024, the company received a warning letter from the Guangdong Securities Regulatory Bureau due to issues related to revenue recognition, construction in progress, goodwill impairment, and internal control, and has actively rectified these issues and submitted a written rectification report [4] Group 2 - The company has established a long-term mechanism to protect its interests, ensuring compliance with information disclosure obligations and preventing the direct or indirect occupation of company funds or resources [2] - The company has complied with relevant regulations regarding the use of raised funds, ensuring that any changes in fund usage are properly disclosed and do not involve high-risk investments during the commitment period [2]

财通证券股份有限公司 关于广东宝莱特医用科技股份有限公司 向特定对象发行股票项目持续督导保荐总结报告书 广东宝莱特医用科技股份有限公司（以下简称"宝莱特"或"公司"）于 2020年9月向不特定对象发行可转债募集资金2.19亿元，期限6年，开源证券股 份有限公司担任保荐机构及主承销商。 公司于2022年1月向特定对象发行股票募集资金5.40亿元，财通证券股份有 限公司（以下简称"财通证券"）担任保荐机构及主承销商。根据《证券发行 上市保荐业务管理办法》等相关规定，财通证券需承接开源证券股份有限公司 尚未完成的持续督导工作，并履行公司向特定对象发行股票上市后的持续督导 职责，持续督导期至2024年12月31日止。 截至本报告签署日，公司持续督导期限已届满。财通证券根据《证券发行 上市保荐业务管理办法》等相关规定，出具本保荐总结报告书。 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担 法律责任。 2、本保荐机构及本人自愿接受中国证监会对保荐总结报告书相关事项进行 的任何质询和调查。 3、本保荐机构 ...

2 | 1.是否建立了防止控股股东、实际控制人及其关 | | | --- | --- | | 联人直接或者间接占用上市公司资金或者其他资 | √ | | 源的制度 | | | 2.控股股东、实际控制人及其关联人是否不存在 | | | 直接或者间接占用上市公司资金或者其他资源的 | √ | | 情形 | | | 3.关联交易的审议程序是否合规且履行了相应的 | √ | | 信息披露义务 | | | 4.关联交易价格是否公允 | √ | | 5.是否不存在关联交易非关联化的情形 | √ | | 6.对外担保审议程序是否合规且履行了相应的信 | √ | | 息披露义务 | | | 7.被担保方是否不存在财务状况恶化、到期不清 | √ | | 偿被担保债务等情形 | | | 8.被担保债务到期后如继续提供担保，是否重新 | √ | | 履行了相应的审批程序和披露义务 | | | （五）募集资金使用 | | | 现场检查手段（包括但不限于本指引第33条所列） | | | 1.是否在募集资金到位后一个月内签订三方监管 | √ | | 协议 | | | 2.募集资金三方监管协议是否有效执行 | √ | | 3.募集资金是否 ...

一、保荐工作概述 | 项目 | | | | | | 工作内容 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1.公司信息披露审阅情况 | | | | | | | | | | | | | | | （1）是否及时审阅公司信息披露文件 | | | | | | 是 | | | | | | | | | （2）未及时审阅公司信息披露文件的次数 | | | | | | 无 | | | | | | | | | 2.督导公司建立健全并有效执行规章制度 | | | | | | | | | | | | | | | 的情况 | | | | | | | | | | | | | | | （1）是否督导公司建立健全规章制度（包 括但不限于防止关联方占用公司资源的制 | | | | | | | | | | 是 | | | | | 度、募集资金管理制度、内控制度、内部 | | | | | | | | | | | | | | | 审计制度、关联交易制度） | | | | | | | | ...

Core Viewpoint - The company reported a significant decline in revenue and profit for the year 2024, primarily due to reduced sales of high-margin monitoring equipment and the impact of centralized procurement policies [1][4]. Revenue Performance - The total revenue for 2024 was 1.06 billion yuan, a year-on-year decrease of 11.18% [1]. - Sales revenue from monitoring equipment dropped by 1.17 billion yuan, a staggering decline of 69.77%, directly affecting overall profit performance [4]. - The renal medical segment showed relative stability with sales revenue of 804 million yuan, a slight increase of 0.91% [4]. Product Development and Innovation - The company continued to invest in R&D, launching several innovative products, including the Biofluid fluid balance management system and the BioView anesthesia video laryngoscope [5]. - New blood dialysis devices were introduced, which received regulatory approval, enhancing the product line and improving patient experience [6]. Market Strategy and Challenges - Centralized procurement policies significantly impacted the company's performance, leading to price pressures on blood dialysis consumables [7]. - The company successfully won bids in a procurement alliance across 22 provinces but faced limitations on revenue growth due to pricing pressures [7]. - To counter these challenges, the company is actively expanding into overseas markets and optimizing internal management to enhance operational efficiency [7].

证券代码：300246 证券简称：宝莱特 公告编号：2025-026 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于公司董事、副总裁兼核心技术人员退休离职的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 广东宝莱特医用科技股份有限公司（以下简称"公司"）董事会于2025年4月 28日收到公司董事、副总裁兼核心技术人员梁瑾女士的书面辞呈。梁瑾女士因退 休申请辞去公司董事、副总裁兼核心技术人员等职务，上述职务原定任期至公司 第八届董事会届满（即2022年12月26日至2025年12月25日）。梁瑾女士辞去上述 职务后，不再担任公司及子公司任何职务，将不再被认定为公司核心技术人员。 根据《公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第2号——创业板上市公司规范运作》《公司章程》等相关规 定，梁瑾女士的辞职申请自书面辞呈送达公司董事会之日起生效。梁瑾女士的离 职不会导致公司董事会成员低于法定最低人数，其离职不会影响公司及董事会的 正常运作，公司将按照相关规定尽快完成董事补选的工作。 梁瑾女士在公 ...

财通证券股份有限公司 （二）核心技术人员参与的项目及专利情况 梁瑾女士在公司任职期间参与的研发项目工作，目前已经完成工作交接，其 辞任上述职务不会对项目的研发进程产生重大不利影响。梁瑾女士在任职期间参 与研发的知识产权均归公司所有，不存在涉及职务成果、知识产权的纠纷或潜在 纠纷，梁瑾女士辞任上述职务不影响公司知识产权的完整性。 （三）履行保密义务情况 关于广东宝莱特医用科技股份有限公司 核心技术人员离职的核查意见 财通证券股份有限公司（以下简称"财通证券"或"保荐机构"）作为广东 宝莱特医用科技股份有限公司（以下简称"宝莱特"或"公司"）的持续督导保 荐机构，根据有关法律法规和规范性文件的要求，对宝莱特核心技术人员离职的 事项进行了审慎核查，核查情况如下： 一、技术人员离职的具体情况 （一）核心技术人员的具体情况 梁瑾，女，1974 年生，中国国籍，无境外永久居留权，本科学历。1996 年 加盟宝莱特电子，历任硬件工程师、项目经理、系统工程师、研发中心总监。现 任公司董事、副总裁、总工程师，全资子公司辽宁恒信生物科技有限公司董事、 孙公司南昌宝莱特医疗器械有限责任公司董事。 截至本核查意见出具日，梁瑾女士直接 ...

Financial Performance - In Q1 2025, the company's operating revenue was 247,732,813.14 CNY, a decrease of 7.17% compared to the same period last year [5] - The net profit attributable to shareholders was 14,448,489.46 CNY, showing a significant increase of 298.35% year-on-year [5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 338,833.92 CNY, up 105.49% from the previous year [5] - Basic earnings per share reached 0.0546 CNY, reflecting a year-on-year growth of 298.54% [5] Market and Policy Impact - The implementation of new policies, such as the "Action Plan for Promoting Large-Scale Equipment Updates and Consumer Goods Replacement," is expected to positively impact the company's monitoring and dialysis product lines [2] - Increased demand for monitoring equipment is anticipated due to the policy-driven replacement of outdated devices in public hospitals and grassroots medical institutions [2] - The company aims to leverage these policies to enhance market share through product upgrades and expanded marketing efforts [2] Industry Trends - The blood dialysis market is projected to experience increased competition over the next 3-5 years, with market concentration expected to rise as leading companies consolidate their positions [3] - Technological advancements, such as home dialysis and smart monitoring, are anticipated to become new growth points, favoring early adopters [4] - The emergence of new markets, particularly in China and India, is expected to challenge international giants as local companies offer competitive pricing [4] Product Development and Innovation - The company plans to focus on developing intelligent medical devices that address clinical needs, with an emphasis on innovative solutions in the renal care sector [5] - New products, including a polypropylene blood dialysis device and specialized dialysis solutions, are set to be launched in 2024 [4] - The company is also working on a new CRRT machine that will integrate with its overall life support solutions [5] Revenue Breakdown - In 2024, the life information and support segment generated sales revenue of 243,502,800 CNY, accounting for approximately 23% of total revenue [6] - The renal medical segment achieved sales revenue of 804,300,500 CNY, representing about 76% of total revenue [6] Strategic Focus for 2025 - The company will concentrate on its two main business areas, aiming to capitalize on opportunities from medical infrastructure expansion and domestic product substitution [8] - Plans include enhancing the penetration of high-margin products in critical care and surgical anesthesia [8] - The company will also strengthen its supply chain and production efficiency to align with procurement policies and improve overall operational effectiveness [8]